Precautions related to cancer patients receiving radioactive isotope treatments such as PLUVICTO and LUTATHERA After radioligand cancer treatment, radiation will be present in the recipient’s body, blood, and urine. The radioactive material will be naturally eliminated from the body via excretion and decay, resulting in a rapid decrease in…
What you need to know before, during, and after treatment.
Pluvicto, a targeted therapy for progressive, PSMA-positive metastatic castration-resistant prostate cancer, has been approved for clinical use by the FDA. On April 26, UF Health Radiation Oncology became the first in the state of Florida to administer it to patients.* Pluvicto is a next generation radioligand treatment…
PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)* PLUVICTO is radiopharmaceutical used to treat adults with advanced prostate cancer that is prostate-specific membrane antigen–Âpositive (PSMA-positive), metastatic and castration-resistant (mCRPC). PSMA-positive prostate cancers can be detected by a special PET scan. PLUVICTO is a treatment option for PSMA-positive mCRPC that…
NATIONALLY RANKED
Nationally ranked in 6 adult specialties and 6 pediatric specialties and rated high performing in 4 adult specialties and 5 procedures and conditions.
DEFINING OPTIMAL TREATMENTS
The seminar has three concurrent programs for radiation therapy, oncology nursing, and radiation oncology.
EXPLORE THE
Our Mission is to prevent, detect, treat and ultimately cure cancer while addressing the unique challenges of the cancer burden faced by the people we serve.
